The global pharmaceutical industry experienced an 18% decline in the number of microbiome-related patent applications in Q2 2023 compared with the previous quarter. The total number of microbiome-related grants dropped by 33% in Q2 2023, according to GlobalData’s Patent Analytics. GlobalData’s Microbiome-Targeting Therapeutics in Infectious Diseases – Thematic Research report provides information on market classification by therapy and technologies, regulatory and market access details for live biotherapeutic products (LBP) in the US and 5EU, and product & company profiles. It helps identify which indications are the mo Buy the report here.
Notably, the number of microbiome-related patent applications in the pharmaceutical industry was 102 in Q2 2023, versus 125 in the prior quarter.
The top five companies accounted for 20% of patenting activity
Analysis of patenting activity by companies shows that DSM-Firmenich filed the most microbiome patents within the pharmaceutical industry in Q2 2023. The company filed 8 microbiome-related patents in the quarter, compared with 9 in the previous quarter. It was followed by Givaudan with 6 microbiome patent filings, AOBiome (2 filings), and French National Institute of Health and Medical Research (2 filings) in Q2 2023.
Patenting activity was driven by the US with a 43% share of total patent filings
The largest share of microbiome related patent filings in the pharmaceutical industry in Q2 2023 was in the US with 43%, followed by Japan (10%) and China (8%). The share represented by the US was 2% higher than the 42% share it accounted for in Q1 2023.
For further understanding of GlobalData's Microbiome-Targeting Therapeutics in Infectious Diseases – Thematic Research buy the report here.